Advertisement

Topics

CARA Abuzz, CERS Up 20% In 5 Days, KURA Turns Heads, JNCE Making Iconic Moves

19:41 EST 24 Jan 2018 | RTTNews

Cara Therapeutics Inc. gained 17.20% to close Wednesday's trading at $16.08. The Company's lead drug candidate is I.V. CR845, which is under a phase III safety study for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients. The first phase III pivotal efficacy trial is expected to be initiated soon.

Original Article: CARA Abuzz, CERS Up 20% In 5 Days, KURA Turns Heads, JNCE Making Iconic Moves

NEXT ARTICLE

More From BioPortfolio on "CARA Abuzz, CERS Up 20% In 5 Days, KURA Turns Heads, JNCE Making Iconic Moves"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...